INTS vs OGN
Intensity Therapeutics, Inc. Common stock (INTS) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
INTS does not have a complete income-statement cache yet.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
INTS currently screens at market cap $7.7M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the INTS and OGN stock pages for the full models.
Not investment advice.